Jiangsu Hengrui Medicine Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Health CarePharmaceuticals & Biotechnology
  • Price (CNY)86.75
  • Today's Change-0.20 / -0.23%
  • Shares traded12.34m
  • 1 Year change21.19%
  • Beta0.6422
Data delayed at least 15 minutes, as of Nov 30 2020 03:29 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.

  • Revenue in CNY (TTM)25.76bn
  • Net income in CNY5.85bn
  • Incorporated1997
  • Employees24.43k
  • Location
    Jiangsu Hengrui Medicine Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
  • Phone+86 51 881220983
  • Fax+86 51 885453845
  • Websitehttp://www.hrs.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
WuXi AppTec Co Ltd15.41bn2.46bn249.81bn21.74k97.587.46--,632.106.90--8.46--37.36--16.10--2.94427.090.128--33.89---17.96------
WuXi Biologics (Cayman) Inc4.32bn1.30bn260.14bn5.69k200.1518.36159.7160.190.37520.37521.254.090.27945.433.27898,927.608.357.799.849.9241.5540.3529.8921.472.77--0.21080.0057.1864.3960.7789.05129.29--
Jiangsu Hengrui Medicine Co Ltd25.76bn5.85bn458.53bn24.43k68.1413.47--17.801.261.265.546.390.88082.184.551,054,261.0019.9620.7422.5623.6786.8986.7822.6623.406.08--0.0015.5933.7025.5931.0528.5913.4646.37
DAIICHI SANKYO COMPANY, LIMITED62.06bn7.35bn506.95bn15.35k63.195.5146.978.1759.7159.71504.59685.340.47651.863.3064,007,560.005.644.146.655.0565.9364.2311.838.473.86--0.121255.535.601.3237.9022.53-11.093.13
CSL Limited60.38bn13.87bn678.68bn27.00k48.9515.7340.7811.246.276.2727.2819.520.65881.205.19460,298.8015.1416.4317.9319.8057.1154.4622.9821.561.3720.210.478744.457.1710.219.588.8027.019.79
Data as of Nov 30 2020. Currency figures normalised to Jiangsu Hengrui Medicine Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

7.32%Per cent of shares held by top holders
HolderShares% Held
Invesco Advisers, Inc.as of 31 Oct 202069.14m1.31%
GF Fund Management Co., Ltd.as of 30 Jun 202056.33m1.06%
China Investment Corp. (Investment Management)as of 30 Sep 202049.27m0.93%
E Fund Management Co., Ltd.as of 30 Jun 202046.00m0.87%
China Asset Management Co., Ltd.as of 06 Nov 202041.04m0.78%
China Universal Asset Management Co., Ltd.as of 30 Jun 202030.23m0.57%
UBS Asset Management (Singapore) Ltd.as of 30 Sep 202028.42m0.54%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 202024.17m0.46%
UBS Asset Management (Hong Kong) Ltd.as of 30 Sep 202021.66m0.41%
JPMorgan Asset Management (Asia Pacific) Ltd.as of 31 Oct 202021.09m0.40%
More ▼
Data from 30 Jun 2020 - 26 Nov 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.